Published in J Clin Oncol on October 14, 2008
Incidence and predictive factors of clinically relevant bile leakage in the modern era of liver resections. HPB (Oxford) (2012) 1.31
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol (2012) 1.15
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer (2011) 1.00
Liver-directed therapies in metastatic colorectal cancer. J Gastrointest Oncol (2014) 0.97
Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol (2011) 0.95
Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys (2015) 0.93
Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB (Oxford) (2010) 0.91
Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg (2010) 0.90
Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Int J Clin Oncol (2011) 0.88
Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. Surg Today (2013) 0.86
Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. Br J Cancer (2012) 0.85
Novel prediction score including pre- and intraoperative parameters best predicts acute kidney injury after liver surgery. World J Surg (2013) 0.83
Bevacizumab and postoperative complications after hepatic surgery for colorectal metastases. J Clin Oncol (2009) 0.81
How many patients and how many complications does it take to decide if a drug is safe to use before surgery? J Clin Oncol (2009) 0.81
Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future. Indian J Urol (2009) 0.81
Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol (2011) 0.79
Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases. World J Gastroenterol (2013) 0.79
Anti-angiogenic agents in metastatic colorectal cancer. World J Gastrointest Oncol (2015) 0.79
Curative strategies for liver metastases from colorectal cancer: a review. Oncologist (2012) 0.78
Systemic treatment of liver metastases from colorectal cancer. Ther Adv Med Oncol (2013) 0.78
Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am (2010) 0.78
Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Int J Colorectal Dis (2011) 0.78
Advances in therapeutics for liver metastasis from colorectal cancer. World J Gastrointest Oncol (2010) 0.77
Hepatic artery dissection in a patient on bevacizumab resulting in pseudoaneurysm formation. Semin Intervent Radiol (2011) 0.77
Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst (2014) 0.76
Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases. BMC Cancer (2016) 0.75
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? Ther Adv Med Oncol (2013) 0.75
Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford) (2013) 0.75
Hepatectomy for Colorectal Cancer Liver Metastases in the Era of Modern Preoperative Chemotherapy: Evaluation of Postoperative Complications. World J Surg (2016) 0.75
Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis. Langenbecks Arch Surg (2017) 0.75
Drug development: Raise standards for preclinical cancer research. Nature (2012) 20.64
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 15.05
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA (1995) 11.90
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry (1996) 7.80
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg (2004) 6.75
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst (2007) 5.48
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg (2005) 4.86
Differences in the use of psychiatric outpatient services between the United States and Ontario. N Engl J Med (1997) 4.78
Risk-adjusted pathologic margin positivity rate as a quality indicator in rectal cancer surgery. J Clin Oncol (2014) 4.59
Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry (1999) 4.57
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol (2008) 4.37
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg (2007) 4.09
Childhood abuse and lifetime psychopathology in a community sample. Am J Psychiatry (2001) 4.07
Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res (2006) 3.65
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol (2007) 3.45
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg (2008) 3.36
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Adequacy and duration of antidepressant treatment in primary care. Med Care (1992) 3.04
Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.96
Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res (2009) 2.93
Mammalian pharmacokinetics of carbon nanotubes using intrinsic near-infrared fluorescence. Proc Natl Acad Sci U S A (2006) 2.91
Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med (2011) 2.91
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol (2003) 2.85
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer (2007) 2.83
Rethinking practitioner roles in chronic illness: the specialist, primary care physician, and the practice nurse. Gen Hosp Psychiatry (2001) 2.82
Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res (2008) 2.75
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol (2007) 2.72
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol (2009) 2.69
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer (2011) 2.68
Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg (2004) 2.62
Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg (2002) 2.62
Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg (2007) 2.62
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol (2009) 2.52
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg (2009) 2.44
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol (2012) 2.43
Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol (2006) 2.43
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl (2005) 2.43
Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol (2007) 2.40
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol (2005) 2.38
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Systematic use of an intraoperative air leak test at the time of major liver resection reduces the rate of postoperative biliary complications. J Am Coll Surg (2013) 2.36
Preoperative portal vein embolization for extended hepatectomy. Ann Surg (2003) 2.33
The Drosophila RAD21 cohesin persists at the centromere region in mitosis. Curr Biol (2000) 2.29